Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.79 |
| ▸ | TNFRSF1A | P19438 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.65 |
| ▸ | P4HB | P07237 | 5/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10582964 | 1.00 | ABCG2 (0.79) | ABCG2TNFRSF1AMEN1KMT2ALMNA | |
| SCHEMBL15807424 | 0.90 | ABCG2 (0.63) | ABCG2TNFRSF1AMEN1KMT2ALMNA | |
| SCHEMBL14306013 | 0.87 | ABCG2 (0.79) | ABCG2TNFRSF1ALMNAMAPTABCB1 | |
| SCHEMBL15807742 | 0.86 | P4HB (0.83) | ABCG2TNFRSF1AMEN1KMT2AABCB1 | |
| SCHEMBL25221520 | 0.85 | P4HB (0.73) | ABCG2TNFRSF1AMEN1KMT2ALMNA | |
| SCHEMBL30384349 | 0.85 | P4HB (0.73) | ABCG2TNFRSF1AMEN1KMT2ALMNA | |
| SCHEMBL30382589 | 0.85 | P4HB (0.73) | ABCG2TNFRSF1AMEN1KMT2ALMNA | |
| SCHEMBL25285091 | 0.85 | P4HB (0.73) | ABCG2TNFRSF1AMEN1KMT2ALMNA | |
| SCHEMBL2458577 | 0.84 | ABCG2 (1.00) | ABCG2TNFRSF1AMEN1KMT2ALMNA | |
| SCHEMBL2458579 | 0.84 | ABCG2 (1.00) | ABCG2TNFRSF1AMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10737995-B2 | Nuclear receptor modulators and their use for the treatment and prevention of cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190047932-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2019-02-14 | — | — | US | disclosed |
| US-20140171503-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | HUMAN SERVICES (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2012174436-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-12-20 | — | — | WO | disclosed |
| EP-0307762-A1 | Acrylic-acid amides and their use as fungicides | F. HOFFMANN-LA ROCHE AG (CH) | 1989-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047932-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | AR, NCOA1, NR5A1 | ABCG2 742/4885TNFRSF1A 777/4885MEN1 2036/4885 |
| US-10737995-B2 | Nuclear receptor modulators and their use for the treatment and prevention of cancer | AR, NCOA1, NR5A1 | ABCG2 742/4885TNFRSF1A 777/4885MEN1 2036/4885 |
| US-20140171503-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | AR, NCOA1, NR5A1 | ABCG2 742/4885TNFRSF1A 777/4885MEN1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.